Seattle Convention Center | Arch at 705 Pike, Seattle, WA
Endocrine Therapy
Thursday, April 30
8:00 AM–10:30 AM
8:00 AM–10:30 AM
Course Moderators: Julie A. Margenthaler, MD, FACS; Anna Weiss, MD, FACS
Faculty: Carla S. Fisher, MD, MBA, FACS; Julie A. Margenthaler, MD, FACS; Alyssa Throckmorton, MD, FACS; Anna Weiss, MD, FACS; Austin D. Williams, MD, MSEd, FACS
Course Description:
Participants will learn the data supporting the use of both neoadjuvant and adjuvant endocrine therapy, as well as CDK4/6 inhibitors, for patients with hormone-receptive breast cancer. There will also be a focus on surgeons as prescribers and managing patient side effects and potential complications.
Course Objectives:
At the conclusion of this course, participants should be able to:
- Discuss the landmark neoadjuvant and adjuvant endocrine therapy trials.
- Identify the optimum genomic assays for specific patient scenarios and understand how to interpret the results.
- Describe methods for mitigating side effects of endocrine therapy.
CME Credit Information:
The American Society of Breast Surgeons designates this live activity for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Onsite Agenda:
| 7:00 AM |
Breakfast
|
| 8:00 AM |
Welcome and Introduction
Julie A. Margenthaler, MD, FACS; Anna Weiss, MD, FACS |
| 8:10 AM |
Neoadjuvant Endocrine Therapy: Which Patients Benefit Most?
Julie A. Margenthaler, MD, FACS |
| 8:35 AM |
Genomic Assays: Choosing the Right Test and Interpreting the Results
Carla S. Fisher, MD, MBA, FACS |
| 9:00 AM |
Adjuvant Endocrine Therapy: Landmark Trials and How to Determine Which to Use
Anna Weiss, MD, FACS |
| 9:25 AM |
Managing the Side Effects of Endocrine Therapy
Alyssa Throckmorton, MD, FACS |
| 9:50 AM |
Combination Therapy: When Should CDK4/6 Inhibitors Be Considered
Austin D. Williams, MD, MSEd, FACS |
| 10:15 AM |
Q&A
|
| 12:00 PM |
Lunch
|
